Oslo, 4 December 2019: Ultimovacs ASA (“Ultimovacs” or “Company”, ticker
ULTIMO), a pharmaceutical company developing novel immunotherapies against
cancer, announces that long-term results from a clinical study with UV1 in
malignant melanoma will be presented during a poster session at the 2020
ASCO-SITC Clinical Immuno-Oncology Symposium. 

The 2020 ASCO-SITC Clinical Immuno-Oncology Symposium will be held in Orlando,
Florida, USA on 6-8 February, 2020. The poster will be presented on 7 February
2020. The poster is named “A Phase I/IIa Clinical Trial Investigating the
Therapeutic Cancer Vaccine UV1 in Combination with Ipilimumab in Patients with
Malignant Melanoma: 4-year Survival Update”. 

The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting focused
on clinical and translational research in immuno-oncology and the implications
for clinical care. The symposium is organized by the American Society of
Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).
ASCO is a professional organization for physicians and oncology professionals
caring for people with cancer. SITC is a professional society of scientists,
academicians, researchers, clinicians, government representatives, and industry
leaders from around the world dedicated to improving cancer patient outcomes by
advancing the science and application of cancer immunotherapy. 

UV1 is a peptide-based vaccine inducing a specific T cell response against the
universal cancer antigen telomerase. UV1 is being developed as a therapeutic
cancer vaccine which may serve as a platform for use in combination with other
immuno-oncology drugs which require an ongoing T cell response for their mode of
action.


For further information, please see www.ultimovacs.com or contact:

Øyvind Kongstun Arnesen, CEO 
oeyvind.arnesen@ultimovacs.com, +47 469 33 810 

Hans Vassgård Eid, CFO 
hans.eid@ultimovacs.com, +47 469 19 822